Edition:
United Kingdom

Aptinyx Inc (APTX.OQ)

APTX.OQ on NASDAQ Stock Exchange Global Select Market

3.66USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$3.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
95,597
52-wk High
$32.25
52-wk Low
$3.45

Latest Key Developments (Source: Significant Developments)

Data In Parkinson's Disease Model In Non-Human Primates Demonstrate Reversal Of Cognitive Deficits With Novel Nmda Receptor Modulator, Nyx-458
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Aptinyx Inc ::DATA IN PARKINSON'S DISEASE MODEL IN NON-HUMAN PRIMATES DEMONSTRATE REVERSAL OF COGNITIVE DEFICITS WITH NOVEL NMDA RECEPTOR MODULATOR, NYX-458.APTINYX INC - ADMINISTRATION OF NYX-458 RESULTED IN RAPID, ROBUST, AND LONG-LASTING IMPROVEMENTS IN COGNITIVE PERFORMANCE ACROSS BATTERY OF TESTS.APTINYX INC - APTINYX PLANS TO INITIATE A PHASE 2 STUDY IN PEOPLE WITH PARKINSON'S DISEASE IN SECOND HALF OF 2019..APTINYX INC - EXPECTS TO REPORT DATA FROM PHASE 1 NYX-458 STUDY IN FIRST HALF OF 2019..  Full Article

Aptinyx Reports Top-Line Results From Phase 2 Clinical Study Of NYX-2925
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Aptinyx Inc ::EXPECTS TO ANNOUNCE DATA FROM FULL ANALYSIS OF PHASE 2 STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA IN H1 2019 .APTINYX REPORTS TOP-LINE RESULTS FROM PHASE 2 CLINICAL STUDY OF NYX-2925 IN PAINFUL DIABETIC PERIPHERAL NEUROPATHY.NYX-2925 WAS WELL-TOLERATED WITH NO SIGNIFICANT ADVERSE EVENTS.NYX-2925 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT SEPARATION FROM PLACEBO ON PRIMARY ENDPOINT.NYX-2925 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT SEPARATION FROM PLACEBO ON PRIMARY ENDPOINT.OF THREE DOSE LEVELS EVALUATED, 50 MG SHOWED MOST MEANINGFUL IMPROVEMENTS ACROSS MULTIPLE MEASURES.  Full Article

Aptinyx Reports Positive Data From Interim Analysis Of Exploratory Study Of NYX-2925 In Subjects With Fibromyalgia
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Aptinyx Inc ::APTINYX REPORTS POSITIVE DATA FROM INTERIM ANALYSIS OF EXPLORATORY STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA.APTINYX INC - OBSERVED CORRESPONDING TRENDS OF IMPROVEMENT ON MULTIPLE SECONDARY ENDPOINTS.APTINYX INC - NYX-2925 WAS WELL TOLERATED WITH NO SUBJECTS REPORTING TREATMENT-RELATED SERIOUS ADVERSE EVENTS.APTINYX INC - NYX-2925 STUDY IS ONGOING WITH FULL DATA EXPECTED TO READ OUT IN FIRST HALF OF 2019.APTINYX INC - EXPECTS TO INITIATE A LARGER PHASE 2 STUDY OF NYX-2925 IN SUBJECTS WITH FIBROMYALGIA IN 2019.APTINYX INC - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY IMAGING-BASED ENDPOINT, CHANGES IN MARKERS OF CENTRAL PAIN PROCESSING, IN 11 SUBJECTS.  Full Article

Aptinyx Q3 Loss Per Share $0.43
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Aptinyx Inc ::APTINYX REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE VIEW $-1.01 -- THOMSON REUTERS I/B/E/S.PLANS TO ANNOUNCE DATA FROM INTERIM ANALYSIS OF EXPLORATORY FIBROMYALGIA STUDY IN DECEMBER 2018.  Full Article

Aptinyx Completes Enrollment In Phase 2 Study Of Nyx-2925 For Painful Diabetic Peripheral Neuropathy
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Aptinyx Inc ::APTINYX COMPLETES ENROLLMENT IN PHASE 2 STUDY OF NYX-2925 FOR PAINFUL DIABETIC PERIPHERAL NEUROPATHY.APTINYX INC - TOP-LINE DATA EXPECTED EARLY IN Q1 OF 2019.APTINYX INC - STUDY IS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.  Full Article

Frazier Life Sciences VIII LP Reports 9.5 Pct Stake In Aptinyx Inc
Thursday, 5 Jul 2018 

July 5 (Reuters) - Aptinyx Inc ::FRAZIER LIFE SCIENCES VIII LP SAYS REPORTS 9.5 PERCENT STAKE IN APTINYX INC AS OF JUNE 25 - SEC FILING.FRAZIER LIFE SCIENCES VIII LP SAYS ACQUIRED APTINYX INC SHARES FOR INVESTMENT PURPOSES.  Full Article

Bain Capital Life Sciences Fund LP Reports A 6.2 Pct Stake In Aptinyx As Of June 25
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Aptinyx Inc ::BAIN CAPITAL LIFE SCIENCES FUND LP REPORTS A 6.2 PCT STAKE IN APTINYX AS OF JUNE 25 - SEC FILING.  Full Article

New Leaf Ventures III Lp Reports 8.7 Percent Stake In Aptinyx Inc As Of June 25 - SEC Filing
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Aptinyx Inc ::NEW LEAF VENTURES III LP REPORTS 8.7 PERCENT STAKE IN APTINYX INC AS OF JUNE 25 - SEC FILING.NEW LEAF VENTURES III LP SAYS ACQUIRED AN INTEREST IN APTINYX INC FOR INVESTMENT PURPOSES.  Full Article

Longitude Capital Partners II Reports A 9.5 Pct Stake In Aptinyx As Of June 25
Monday, 2 Jul 2018 

July 2 (Reuters) - Aptinyx Inc ::LONGITUDE CAPITAL PARTNERS II LLC REPORTS A 9.5 PCT STAKE IN APTINYX INC <<>> AS OF JUNE 25 - SEC FILING.  Full Article

Aptinyx Shares Debut At $17.40, About 8.8 Pct Above IPO Price
Thursday, 21 Jun 2018 

June 21 (Reuters) - Aptinyx Inc ::APTINYX SHARES DEBUT AT $17.4 ON THE NASDAQ VERSUS IPO PRICE OF $16/SHARE.  Full Article